←
Omar Makram Elsayed, MD MPH (Omar M Makram)265 posts
Omar Makram Elsayed, MD MPH (Omar M Makram) avatar

Omar Makram Elsayed, MD MPH (Omar M Makram)

@OelsayedMD

IM @MCG_InternalMed | @AHAScience #SFRN CardioOnc fellow 🫀| MPH @LSHTM 🇬🇧 | MSc @gtomsanalytics 🐝 I Postdoc @MethodistHosp | MD 🇪🇬 |#Epidemiology #Data

◷ Joined March 2022▧ 15 Photos and videos
Khurram Nasir avatar
⟳ Omar Makram Elsayed, MD MPH (Omar M Makram) retweeted
Khurram Nasir@khurramn1·Oct 30

Congratulations to our newly minted and possibly youngest "Professor" @MethodistHosp.....the one and only @Sadeer_AlKindi 🙌🙌 Watching your growth & contributions over the last 3 yrs has been a pure joy. So proud of you, and ur just getting started. Now I have another 'Professor' to convince that my ideas make sense! 😃 @HMethodistCV @WilliamZoghbi

Post attachment
Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC avatar
⟳ Omar Makram Elsayed, MD MPH (Omar M Makram) retweeted
Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC@avirupguha·Feb 27

Great conversations today at #GU26 @ASCO (ASCO) ! @DocHariKris and I presented two posters focused on cardio-oncology, implementation, and health equity in prostate cancer. Today’s posters: •County-level educational attainment and long-term outcomes in older men with prostate cancer (SEER–Medicare 2009–2017). @virajshahr Key takeaway: Men living in lower-education counties experienced higher cardiovascular and overall mortality—highlighting community education as a potentially actionable lever for geographically targeted survivorship care. •Abstract #523882: Physician perspectives on implementing a cardiovascular risk score for prostate cancer (PRISM-guided evaluation). @ASCOPost Key takeaway: Clinicians prioritize tools that are simple, fast, and workflow-compatible—with a clear preference for lab-independent models to minimize disruption. We thank all the leaders in the field who worked with us to make this study possible. Posting video on the topic here as well @GACancerCenter @neerajaiims @zklaassen_md @mcg_urology @umangtalking @OncoAlert @oncodaily @PCFnews @IrbazRiaz @PBarataMD @AarmstrongDuke @CaPsurvivorship @PhillipKooMD @ZEROCancer @MCGCardFellows all abstracts will be available in @JCO_ASCO . Thanks to @CDMRP and @AHAScience for funding our work.

Post attachmentPost attachment
4:01
Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC avatar
⟳ Omar Makram Elsayed, MD MPH (Omar M Makram) retweeted
Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC@avirupguha·Feb 26

Big day in the poster hall for our group! @DocHariKris and I shared 6 posters today spanning cardio-oncology + multi-omics in prostate cancer: connecting imaging, adiposity, immune remodeling, proteomics, and cardio–kidney–metabolic (CKM) risk. @TarekNahle @neerajaiims @GACancerCenter @anantm Poster lineup: •T1 MRI / radiomics: Skeletal muscle radiomic features on prostate T1-weighted MRI and association with major adverse cardiac events (MACE) @anantm •Obesity-associated epigenetic remodeling under androgen deprivation therapy (ADT) and implications for cardiometabolic risk @ImmunologyAU •CyTOF: CyTOF immune profiling: how obesity shapes biphasic immune remodeling (CD45+ circulating cells) during ADT @ImmunologyAU •Proteomics: Proteomic remodeling after ADT: how age modifies innate immune/complement–ECM pathways @mayo •CardioKidneyMetabolic Syndrome: CKM syndrome stages in prostate cancer and prognostic significance for CV morbidity/mortality •MRI T2 microenvironment: Periprostatic adipose microenvironment remodeling in aggressive prostate cancer (atlas-based geometric analysis) @anantm Really appreciated all the thoughtful questions and conversations: always energizing to share the work and hear new perspectives. If you’re here, come say hi! #ProstateCancer #CardioOncology #Radiomics #Epigenetics #CyTOF #Proteomics #CKM #CancerResearch #TranslationalScience #GU26 @ASCOPost @ASCO @OelsayedMD @EmoryAIHumanity . All abstracts out in @JCO_ASCO . Thanks to @CDMRP and @AHAScience for funding our work.

Post attachmentPost attachmentPost attachmentPost attachment
Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC avatar
⟳ Omar Makram Elsayed, MD MPH (Omar M Makram) retweeted
Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC@avirupguha·10 Nov 2025

Presentation #5 on last day of #AHA25 by @dukemedicine #SarahMalik from @MCG_AUG - Take home - In 12,832 #ARIC participants followed for 28 years, 877 cancer survivors and 3,653 non-cancer participants developed incident CVD. Across both unmatched and propensity-matched analyses, the use of statins, anti-hypertensives, and aspirin was consistently associated with lower CVD risk in both cancer and non-cancer groups. The magnitude of benefit was comparable between groups, indicating that cancer survivors derive similar cardiovascular protection from these preventive medications as individuals without cancer. @JHUBloombergCtr @ShelbyKuttyMD @ICOSociety @oncodaily @OncoAlert

Post attachmentPost attachmentPost attachment
Viraj Shah@virajshahr26 Oct 2025

#AHA25 #CardioOncology Excited to highlight our lab’s #ARIC-cancer work by Dr. Sarah Malik and team: “The Use of Common Cardiovascular Medications Is Associated with a Comparable Decrease in CVD Risk in Cancer Survivors and Non-Cancer Patients.” Join her moderated presentation on Mon, Nov 10 (10:45–10:50 AM CT) in Clinical Science Zone 2.

Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC avatar
⟳ Omar Makram Elsayed, MD MPH (Omar M Makram) retweeted
Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC@avirupguha·10 Nov 2025

Final (#6) presentation of #AHA25 by @MCG_AUG student @sathvika_n focused on disparities in clinical trials - take home - Among 284 Southern U.S. cities, only 26% contained a Phase III lipid-lowering trial site, with a median drive time of 36 minutes to the nearest site. Each one-point increase in Area Deprivation Index (ADI) was linked to a 2.1% longer drive time (p<0.001), and moving from the 25th to 75th ADI percentile more than doubled travel burden. Minority-majority cities had 21.7% shorter drive times, largely due to trial clustering in a few large urban hubs. Overall, more socioeconomically deprived cities faced significantly longer travel distances, underscoring inequitable access to PCSK9 and lipid-lowering clinical trials. @NIMHD @trialradar

Post attachmentPost attachment

#AHA25 Excited to present our work from @MCG_AUG with my team: “Unequal Access: Socioeconomic Deprivation & Travel Distance to Phase III Lipid-Lowering Trials in the Southern U.S.” Join me for my moderated poster session on Mon, Nov 10 (2:06–2:11 PM CT, Population Science Zone)!

Post attachmentPost attachment
Abdelrahman Ali avatar
⟳ Omar Makram Elsayed, MD MPH (Omar M Makram) retweeted
Abdelrahman Ali@Abdelcards·11 Nov 2025

🌟 What an incredible experience presenting at #AHA25! 🎤 Honored to share our collaborative work with Memorial Sloan Kettering—advancing risk prediction in HER2+ breast cancer under the mentorship of @anita_deswal 💙🫀 Grateful for the journey & teamwork #CardioOncology

Post attachment
Abdelrahman Ali avatar
⟳ Omar Makram Elsayed, MD MPH (Omar M Makram) retweeted
Abdelrahman Ali@Abdelcards·9 Nov 2025

🎬 Grateful for the opportunity to join Dr. Fred Kusumoto in providing #AHA25 coverage with @ACCinTouch 💙We discussed standout trials from Day 2️⃣ & previewed upcoming #HeartFailure studies, including POLY-HF & CAVIAR 🫀✨#CardioTwitter

#AHA25: Drs. Fred M. Kusumoto & Abdelrahman Ali discuss the standout trials from Day 2️⃣ & share what they’re looking forward to in upcoming HF studies, including POLY-HF & CAVIAR. 🔗 bit.ly/4oWYKfQ @Abdelcards #ACCAnywhere #CardioX

2:17
Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC avatar
⟳ Omar Makram Elsayed, MD MPH (Omar M Makram) retweeted
Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC@avirupguha·9 Nov 2025

Second presentation for the day by superstar @virajshahr - take home - Among 3,192 African American ARIC participants followed for 22.4 years, 30% developed cancer. The DARC-positive genotype was not significantly associated with overall, smoking-related, or obesity-related cancer risk (HR 0.95, 95% CI 0.83–1.09). However, DARC-null individuals with CVD showed a trend toward higher incidence of smoking-related and lung cancers, suggesting possible effect modification by cardiovascular disease. @OelsayedMD @ICOSociety

Post attachmentPost attachment

Come, check out our work funded by @AHAScience #SFRN. Learn about role of ancestral gene ACKR1 and how that changes cancer risk in those with cardiovascular disease. Previously we had shown the role of neutrophil to lymphocyte ratio. We were fortunate to collaborate with.@MeliD32 @JohnsHopkinsSPH #DrPlatz #AHA25 prior work by @OelsayedMD : ahajournals.org/doi/abs/10.1… and sciencedirect.com/science/ar… @OncoAlert @ICOSociety

Omar Makram Elsayed, MD MPH (Omar M Makram) avatar
Omar Makram Elsayed, MD MPH (Omar M Makram)@OelsayedMD·10 Nov 2025

Thrilled to present our new abstract at #AHA25! 🫀 We compared traditional (BMI> 30) vs. new (BMI> 25 + central adiposity) #obesity definitions in the ARIC study (25-yr follow-up).  Key Results: ✅ The new definition found a large, intermediate-risk group for CVD (aHR 1.25).

Third moderated poster by @OelsayedMD presenting moderated digital poster - take home #1 Among 14,834 ARIC participants followed for 25 years, 54% were classified as obese by the newer central adiposity definition versus 27% by the traditional BMI-based definition. The newly defined group captured individuals with BMI 25–29.9 kg/m² but high waist circumference or ratio, 7% of whom reverted to non-obese status over time. @JHUBloombergCtr

Post attachmentPost attachment
Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC avatar
⟳ Omar Makram Elsayed, MD MPH (Omar M Makram) retweeted
Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC@avirupguha·9 Nov 2025

Third moderated poster by @OelsayedMD presenting moderated digital poster - take home #1 Among 14,834 ARIC participants followed for 25 years, 54% were classified as obese by the newer central adiposity definition versus 27% by the traditional BMI-based definition. The newly defined group captured individuals with BMI 25–29.9 kg/m² but high waist circumference or ratio, 7% of whom reverted to non-obese status over time. @JHUBloombergCtr

Post attachmentPost attachment

Obesity is an important overlap between cancer and cardiovascular disease. We talk about it here: pubmed.ncbi.nlm.nih.gov/4084…. How does the new WHO definition: thelancet.com/commissions-do… of obesity shake up this risk factor- come and learn from @OelsayedMD at #AHA25 @AHAScience @ObesityAction @ObesityAdvocacy @LillyObesityInt @ICOSociety

Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC avatar
⟳ Omar Makram Elsayed, MD MPH (Omar M Makram) retweeted
Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC@avirupguha·7 Nov 2025

On the eve of #AHA25, I am happy to report a new paper from our lab looking to replace CHADSVASC for AF in breast cancer. Published in @Cancers_MDPI - BS2CALED - In breast cancer + AF, B‑S2CALED predicts stroke/TIA better than CHA2DS2‑VASc and is externally validated. Simple 0–10 score from routine data to support anticoagulation decisions in oncology. DOI:10.3390/cancers17223600 #CardioOncology #BreastCancer #AFib #Stroke @sdent_cardioonc @nickolastab @Dr_Mike_Fradley @KoberLars

Post attachmentPost attachmentPost attachment
Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC avatar
⟳ Omar Makram Elsayed, MD MPH (Omar M Makram) retweeted
Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC@avirupguha·7 Nov 2025

Why use this calculator? CHA2DS2‑VASc underperforms in cancer. B‑S2CALED improves discrimination (C‑index 0.64 vs 0.54 internal; 0.77 vs 0.53 external) + reclassification, with 3 tiers (0 none, 1–4 low/intermediate, >4 high). #CardioOncology #BreastCancer @ICOSociety @datsunian @Breastcancerorg @DocHariKris @OelsayedMD @virajshahr @OncBrothers @OncoAlert @GACancerCenter

Post attachmentPost attachment
Sathvika N avatar
⟳ Omar Makram Elsayed, MD MPH (Omar M Makram) retweeted
Sathvika N@sathvika_n·26 Oct 2025

#AHA25 Excited to present our work from @MCG_AUG with my team: “Unequal Access: Socioeconomic Deprivation & Travel Distance to Phase III Lipid-Lowering Trials in the Southern U.S.” Join me for my moderated poster session on Mon, Nov 10 (2:06–2:11 PM CT, Population Science Zone)!

Post attachmentPost attachment
Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC avatar
⟳ Omar Makram Elsayed, MD MPH (Omar M Makram) retweeted
Avirup Guha MD, MPH, MBA, FICOS, FACC, FAHA, FESC@avirupguha·26 Oct 2025

Excellent disparities work in access to modern lipid lowering trials by M1 at @MCG_AUG @sathvika_n . Inspired by an unexplained denial to an oral PCSK9 phase 3 trial, we wondered what happens when ultra modern medicine is not available to large number of patients due to biased site selection. Come see our unbiased work using @Google API to find distance to trial site. @DrMakaryFDA @US_FDA @neerajaiims @MCGCardFellows @nationallipid @AHAScience @PCSK9Forum #AHA25

#AHA25 Excited to present our work from @MCG_AUG with my team: “Unequal Access: Socioeconomic Deprivation & Travel Distance to Phase III Lipid-Lowering Trials in the Southern U.S.” Join me for my moderated poster session on Mon, Nov 10 (2:06–2:11 PM CT, Population Science Zone)!

Post attachmentPost attachment